A Phase IV Single Arm, Multicenter, Open-label Study Assessing Deep Molecular Response in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive CML in Chronic Phase After Two Years of Treatment With Nilotinib 300mg BID
Phase of Trial: Phase IV
Latest Information Update: 04 Apr 2018
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms NILOdeepR
- Sponsors Novartis
- 25 Aug 2017 Planned End Date changed from 20 Feb 2020 to 18 Feb 2020.
- 25 Aug 2017 Planned primary completion date changed from 20 Feb 2020 to 18 Feb 2020.
- 10 Jun 2017 Biomarkers information updated